CoChat

Products of Vitamin D3 or 7-Dehydrocholesterol Metabolism by Cytochrome P450scc Show Anti-Leukemia Effects, Having Low or Absent Calcemic Activity

Open access

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Cytochrome P450scc metabolizes vitamin D3 to 20-hydroxyvitamin D3 (20(OH)D3) and 20,23(OH)(2)D3, as well as 1-hydroxyvitamin D3 to 1alpha,20-dihydroxyvitamin D3 (1,20(OH)(2)D3). It also cleaves the side chain of 7-dehydrocholesterol producing 7-dehydropregnenolone (7DHP), which can be transformed to 20(OH)7DHP. UVB induces transformation of the steroidal 5,7-dienes to pregnacalciferol (pD) and a lumisterol-like compounds (pL). METHODS AND FINDINGS: To define the biological significance of these P450scc-initiated pathways, we tested the effects of their 5,7-diene precursors and secosteroidal products on leukemia cell differentiation and proliferation in comparison to 1alpha,25-dihydroxyvitamin D3 (1,25(OH)(2)D3). These secosteroids inhibited proliferation and induced erythroid differentiation of K562 human chronic myeloid and MEL mouse leukemia cells with 20(OH)D3 and 20,23(OH)(2)D3 being either equipotent or slightly less potent than 1,25(OH)(2)D3, while 1,20(OH)(2)D3, pD and pL compounds were slightly or moderately less potent. The compounds also inhibited proliferation and induced monocytic differentiation of HL-60 promyelocytic and U937 promonocytic human leukemia cells. Among them 1,25(OH)(2)D3 was the most potent, 20(OH)D3, 20,23(OH)(2)D3 and 1,20(OH)(2)D3 were less active, and pD and pL compounds were the least potent. Since it had been previously proven that secosteroids without the side chain (pD) have no effect on systemic calcium levels we performed additional testing in rats and found that 20(OH)D3 had no calcemic activity at concentration as high as 1 microg/kg, whereas, 1,20(OH)(2)D3 was slightly to moderately calcemic and 1,25(OH)(2)D3 had strong calcemic activity. CONCLUSIONS: We identified novel secosteroids that are excellent candidates for anti-leukemia therapy with 20(OH)D3 deserving special attention because of its relatively high potency and lack of calcemic activity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0009907

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 20(OH)D3 and 1,20(OH)2D3 have less calcemic effect in comparison to 1,25(OH)2D3. In vivo testing of calcemic effects of 20(OH)D3 and 1,20(OH)2D3 in comparison to 1,25(OH)2D3.
Figure 1 20(OH)D3 and 1,20(OH)2D3 have less calcemic effect in comparison to 1,25(OH)2D3. In vivo testing of calcemic effects of 20(OH)D3 and 1,20(OH)2D3 in comparison to 1,25(OH)2D3.CC BY · PubMed Central
Figure 2 Novel secosteroids and steroidal 5.7-diene compounds have anti-proliferative effects on leukemia cells. The anti-proliferative effects of novel secosteroidal and steroidal 5,7-diene compounds on Mel mouse erythroleukemia (A), human K562 myeloid (B), HL-60 human promyelocytic (C), U937 promonocytic (D) leukemias. After treatment for 7 days with different compounds (10−7 M), cells were stained with trypan blue and the number of viable cells counted. Statistically significant effects are marked as follow *p<0.05; **p<0.01; ***p<0.001.
Figure 2 Novel secosteroids and steroidal 5.7-diene compounds have anti-proliferative effects on leukemia cells. The anti-proliferative effects of novel secosteroidal and steroidal 5,7-diene compounds on Mel mouse erythroleukemia (A), human K562 myeloid (B), HL-60 human promyelocytic (C), U937 promonocytic (D) leukemias. After treatment for 7 days with different compounds (10−7 M), cells were stained with trypan blue and the number of viable cells counted. Statistically significant effects are marked as follow *p<0.05; **p<0.01; ***p<0.001.CC BY · PubMed Central
Figure 3 Novel secosteroids and steroidal 5.7-diene induce erythroid differentiation in leukemia cells. Induction of erythroid differentiation determined was from the the concentration of hemoglobin in an equal number of cells. Cells were treated for 7 days with different compounds (10−7 M), stained with benzidine solution and the amount of hemoglobin as hemin in Mel (A) or K562 (B) leukemia cells was determined by measuring the absorbance at 600 nm after lysis of the cells. ***p<0.001. C.The number of benzidine positive K562 cells after 7 days of treatment with different compounds (10−7 M). Cells were stained with benzidine solution and the number of benzidine positive (blue) cells was determined by counting 200 cells per microscopic field. The results are present as % of benzidine positive cells in comparison to total cell number. *p<0.05; **p<0.01; ***p<0.001.
Figure 3 Novel secosteroids and steroidal 5.7-diene induce erythroid differentiation in leukemia cells. Induction of erythroid differentiation determined was from the the concentration of hemoglobin in an equal number of cells. Cells were treated for 7 days with different compounds (10−7 M), stained with benzidine solution and the amount of hemoglobin as hemin in Mel (A) or K562 (B) leukemia cells was determined by measuring the absorbance at 600 nm after lysis of the cells. ***p<0.001. C.The number of benzidine positive K562 cells after 7 days of treatment with different compounds (10−7 M). Cells were stained with benzidine solution and the number of benzidine positive (blue) cells was determined by counting 200 cells per microscopic field. The results are present as % of benzidine positive cells in comparison to total cell number. *p<0.05; **p<0.01; ***p<0.001.CC BY · PubMed Central
Figure 4 Novel secosteroids and steroidal 5.7-diene induce monocytic differentiation in HL-60 (A, C) and U937 cells (B, D). A and B. Cells were treated for 7 days with different compounds (10−7 M), stained with NBT and the number of NBT positive (blue) cells was determined counting 200 cells per field, and expressed as a % of the total cells. Induction of differentiation measured by the absorbance at 715 nm after lysis of the equal number of NBT stained cells is in C and D. *p<0.05; **p<0.01; ***p<0.001.
Figure 4 Novel secosteroids and steroidal 5.7-diene induce monocytic differentiation in HL-60 (A, C) and U937 cells (B, D). A and B. Cells were treated for 7 days with different compounds (10−7 M), stained with NBT and the number of NBT positive (blue) cells was determined counting 200 cells per field, and expressed as a % of the total cells. Induction of differentiation measured by the absorbance at 715 nm after lysis of the equal number of NBT stained cells is in C and D. *p<0.05; **p<0.01; ***p<0.001.CC BY · PubMed Central
Figure 5 Novel secosteroidal and steroidal 5.7-diene induce the expression of differentiation genes in HL-60 cells. Real time PCR analysis of the expression of CD11b and transferrin genes in HL-60 cells. Cells were treated for 3 days with graded concentrations of 1,25(OH)2D3 (A), 20(OH)D3 (B), 20,23(OH)2D3 (C) and 1,20(OH)2D3 (D), mRNA was isolated and the gene expression analyzed. *p<0.05; **p<0.01; ***p<0.001 determined with one way ANOVA.
Figure 5 Novel secosteroidal and steroidal 5.7-diene induce the expression of differentiation genes in HL-60 cells. Real time PCR analysis of the expression of CD11b and transferrin genes in HL-60 cells. Cells were treated for 3 days with graded concentrations of 1,25(OH)2D3 (A), 20(OH)D3 (B), 20,23(OH)2D3 (C) and 1,20(OH)2D3 (D), mRNA was isolated and the gene expression analyzed. *p<0.05; **p<0.01; ***p<0.001 determined with one way ANOVA.CC BY · PubMed Central
Figure 6 Novel secosteroids and steroidal 5.7-diene induce the expression of markers of differentiation in HL-60 cells. Flow cytometry analysis of CD11b protein expression in HL-60 cells. Cells were treated for 5 days with 10−6 M 1,25(OH)2D3 (A), 20(OH)D3 (B), 20,23(OH)2D3 (C), 1,20(OH)2D3 (D), pD (E) and 20(OH)pD (F), mRNA was isolated and the % of cells expressing CD11b protein determined. *p<0.05; **p<0.01; ***p<0.001.
Figure 6 Novel secosteroids and steroidal 5.7-diene induce the expression of markers of differentiation in HL-60 cells. Flow cytometry analysis of CD11b protein expression in HL-60 cells. Cells were treated for 5 days with 10−6 M 1,25(OH)2D3 (A), 20(OH)D3 (B), 20,23(OH)2D3 (C), 1,20(OH)2D3 (D), pD (E) and 20(OH)pD (F), mRNA was isolated and the % of cells expressing CD11b protein determined. *p<0.05; **p<0.01; ***p<0.001.CC BY · PubMed Central
Figure 7 Novel secosteroids and steroidal 5.7-diene arrest HL-60 cells in G1/G0 phase of the cell cycle. Cell cycle analysis of the HL-60 human promyelocytic human leukemia shows arrest in G1/G0 phase (A). Statistically significant inhibition of S (B) and G2/M (C) phases is also evident for 1,25(OH)2D3, 20(OH)D3, 20,23(OH)2D3, 1,20(OH)2D3 but absent for pD and 20(OH)pD. Representative flow cytometry analysis for 20,23(OH)2D3 is in D. *p<0.05; **p<0.01; ***p<0.001.
Figure 7 Novel secosteroids and steroidal 5.7-diene arrest HL-60 cells in G1/G0 phase of the cell cycle. Cell cycle analysis of the HL-60 human promyelocytic human leukemia shows arrest in G1/G0 phase (A). Statistically significant inhibition of S (B) and G2/M (C) phases is also evident for 1,25(OH)2D3, 20(OH)D3, 20,23(OH)2D3, 1,20(OH)2D3 but absent for pD and 20(OH)pD. Representative flow cytometry analysis for 20,23(OH)2D3 is in D. *p<0.05; **p<0.01; ***p<0.001.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

5 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 156

Metadata

Authors
Slominski, A. T., Janjetovic, Z., Fuller, B. E., Zmijewski, M. A., Tuckey, R. C., Nguyen, M. N., Sweatman, T., Li, W., Zjawiony, J., Miller, D., Chen, T. C., Lozanski, G., & Holick, M. F.
Affiliations
  • University of Tennessee Health Science Center (US)
  • Gdańsk Medical University (PL)
  • The University of Western Australia (AU)
  • University of Mississippi (US)
  • Boston University (US)
  • The Ohio State University (US)
Corresponding author
Slominski, Andrzej T.
Venue
PLoS ONE
Published
2010-03-26
Volume
5
Issue
3
Pages
e9907
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2020048876
Cited by
149
References
54
Citations by year
2025: 3 · 2024: 9 · 2023: 7 · 2022: 13 · 2021: 12 · 2020: 11 · 2019: 4 · 2018: 11 · 2017: 9 · 2016: 9 · 2015: 12 · 2014: 12 · 2013: 7 · 2012: 13
FWCI
8.01
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • UWA Profiles and Research Repository (UWA) (publishedVersion, other-oa)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
  • OpenBU (Boston University) (submittedVersion, cc-by)
Funders
  • National Institutes of Health
  • U.S. Public Health Service (R01A052190)
  • National Institute of Diabetes and Digestive and Kidney Diseases (P30DK040561)
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR052190)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Vitamin D Research Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Photodynamic Therapy Research Studies
Keywords
vitamin D3 metabolism, 7-dehydrocholesterol, cytochrome P450scc, secosteroids, lumisterol, leukemia cell differentiation, leukemia cell proliferation, calcemic activity, chronic myeloid leukemia, promyelocytic leukemia
MeSH terms
Animals, Antineoplastic Agents, Calcifediol, Cholecalciferol, Cholesterol Side-Chain Cleavage Enzyme, Dehydrocholesterols, Humans, Hypercalcemia, Pregnenolone, Gene Expression Regulation, Leukemic, HL-60 Cells, U937 Cells, Cell Line, Tumor, Cell Proliferation, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.